undamentalytics Newsletter
Sign in

Syndax Pharmaceuticals Inc cash flow statement

In fiscal 2025, Syndax Pharmaceuticals Inc's operations generated −$323m of cash; it spent $187,000 on capital projects, leaving free cash flow of −$323m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−2−35−47−69−51−7129−134−161−275−323−177
Depreciation and amortisation0000004333128618
Stock-based pay455669131631434853
Capital spending0000—0000000
Free cash flow−2−35−47−69—−7129−134−161−275−323−177
Free cash flow after stock pay−6−40−53−75—−8016−150−192−318−371−230

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PTGX vs SNDXSNDX vs VIRPHAT vs SNDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Syndax Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Syndax Pharmaceuticals Inc.